Physician profile
Eric A Cline
NPI 1073004719
$8,472.57
in general payments reported to CMS, 2019-2025
39 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2022: $1,705 · 2023: $2,392 · 2024: $2,444 · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,293 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,292.68 |
| Education | $131.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,196.67 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $932.26 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $927.76 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $705.93 | 2022-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $590.55 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $547.21 | 2023-2025 | |
| Astellas Pharma US INC | $450.86 | 2022-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $419.91 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $372.18 | 2021-2024 | Belsomra, Steglatro, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $356.54 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $297.28 | 2022-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.89 | 2022-2025 | Xifaxan |
| Dexcom, INC. | $216.86 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.76 | 2023-2025 | Jardiance |
| Axsome Therapeutics, INC. | $169.65 | 2023-2025 | Sunosi, Auvelity |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $131.72 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Antares Pharma, INC. | $76.88 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Glaxosmithkline, LLC. | $74.25 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $52.94 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $33.72 | 2023-2025 | Keveyis, Gvoke Hypopen |
| Tris Pharma INC | $33.48 | 2025 | Dyanavel Xr, Onyda Xr |
| Abbott Laboratories | $32.32 | 2022 | |
| Abiomed | $31.30 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.90 | 2021 | |
| Idorsia Pharmaceuticals US INC | $29.30 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $28.29 | 2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $25.60 | 2022 | |
| Ardelyx, INC. | $25.36 | 2025 | Ibsrela |
| Jazz Pharmaceuticals INC. | $21.44 | 2021 | |
| Lundbeck LLC | $20.67 | 2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $20.13 | 2025 | Jornay Pm |
| Paratek Pharmaceuticals, INC. | $18.59 | 2024 | Nuzyra |
| Tonix Medicines, INC. | $17.39 | 2025 | Tonmya |
| Acella Pharmaceuticals, LLC | $17.31 | 2025 | NP Thyroid 60 |
| Enterra Medical, INC. | $16.85 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $15.95 | 2021 | |
| Exact Sciences Corporation | $15.90 | 2025 | The Cologuard Plus Collection Kit |
| Tolmar, INC. | $15.81 | 2025 | Jatenzo |
| Phathom Pharmaceuticals, INC. | $15.16 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Cline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.